Early Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People whose brain scans and specialist team assessment suggest a diagnosis of GBM (a type of brain tumour), based on a full brain MRI scan taken within the past 4 weeks
- People whose medical team has determined that surgery is appropriate, followed by the standard combined radiation and chemotherapy treatment plan (known as the Stupp regimen)
- People for whom it is safe to delay surgery by up to 14 days after joining the trial
- People with a life expectancy of more than 3 months
- People with a general health and activity level rated at 2 or below on the WHO Performance Status scale, meaning they are able to carry out some daily activities independently (confirm with trial site)
- People who are able to give written consent to participate
- Women of childbearing potential who are using an approved method of contraception in line with Danish health authority guidelines
- People who have signed the trial consent form
Who may not be able to join:
- People who are pregnant or breastfeeding — women of childbearing potential will be required to take a pregnancy test
- People who have previously been treated with, or have had an allergic reaction to, the trial drugs perampanel or senicapoc
- People for whom either of the trial drugs (senicapoc or perampanel) is medically unsuitable
- People who have had another cancer and completed treatment for it within the five years before joining — except for a type of skin cancer called basal cell carcinoma
- People currently taking certain anti-seizure medicines that affect how the body processes other drugs, specifically carbamazepine, phenytoin, phenobarbital, or primidone
- People with significant liver problems, based on specific blood test results (confirm with trial site)
- People with significant kidney problems, based on a kidney function test result below a certain level (confirm with trial site)
- People with blood clotting problems, based on specific blood test results (confirm with trial site)
- People with a low platelet count in the blood (confirm with trial site)
- People with a low level of a type of white blood cell called neutrophils (confirm with trial site)
- People with anaemia, meaning their haemoglobin level is below a certain threshold (confirm with trial site)
- People with severe difficulties with thinking, memory, or understanding
- People who are currently participating in another clinical trial involving a treatment intervention
- People with any condition that could affect how the body absorbs or processes the trial drugs, such as certain digestive or intestinal conditions (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (+45) 78450000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Maximum tolerable dose of senicapoc monotherapy (mg); Number of patients in each group (2 and 3) excluded from the study due to intolerability when exposed to perampanel at the lowest dose (2 mg)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.